Technology
Health
Pharmaceutical

Aerpio Pharmaceuticals

$1.06
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.07 (-6.25%) Today
+$0.01 (0.95%) After Hours

Why Robinhood?

You can buy or sell ARPO and other stocks, options, ETFs, and crypto commission-free!

About

Aerpio Pharmaceuticals, Inc. Common Stock, also called Aerpio Pharmaceuticals, is a biopharmaceutical company, which engages in the research and development of treatments for ocular diseases. Read More Its product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; and AKB-4924, a selective stabilizer of hypoxia-inducible factor-1 alpha, which has completed a single ascending dose clinical trial for the treatment of inflammatory bowel disease. The company was founded by Joseph H. Garder on November 17, 2011 and is headquartered in Cincinnati, OH.

Employees
27
Headquarters
Cincinnati, Ohio
Founded
—
Market Cap
42.62M
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
144.93K
High Today
$1.15
Low Today
$1.00
Open Price
$1.15
Volume
1.87M
52 Week High
$5.00
52 Week Low
$1.00

Collections

Technology
Health
Pharmaceutical
Biopharmaceutical
Research And Development
2018 IPO
US
North America

News

MarketWatchMar 18

Aerpio Pharmaceuticals stock plummets after failed trial of diabetic retinopathy treatment

Shares of Aerpio Pharmaceuticals Inc. ARPO, -71.29% plummeted 71% toward a record low in active trade Monday, after the biopharmaceutical company said a phase 2b study of its treatment for diabetic retinopathy failed to meet its primary endpoint of improvement over placebo. The stock was the biggest decliner listed on major U.S. exchanges, with volume reaching 5.5 million shares, or about 22 times the full-day average. Meanwhile, the company said the trial of its lead candidate AKB-9778 was found did to be ...

470
StreetInsiderMar 5

Aerpio Pharmaceuticals (ARPO) Tops Q4 EPS by 2c

Aerpio Pharmaceuticals (NASDAQ: ARPO) reported Q4 EPS of ($0.21), $0.02 better than the analyst estimate of ($0.23). “We remain on track to report top-line data from our TIME-2b clinical trial before the end of March,” said Stephen Hoffman, M.D., Ph.D., Chief Executive Officer of Aerpio. “We view the study as an important inflection point for Aerpio and expect to use the results to direct the future development of AKB-9778 in non-proliferative diabetic retinopathy and possibly other conditions associated w...

197

Earnings

-$0.23
-$0.22
-$0.22
-$0.21
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Estimated
—
Actual
Expected May 14, Pre-Market
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.